Chronic hepatic encephalopathy(HE) is a well-accepted complication of chronic liver disease(CLD), and finding the right treatment to reduce HE episodes before liver transplant remains a challenge. Both rifaximin and probiotics are currently used to reduce HE symptoms, but their precise effect on brain metabolites have never been studied. Our aims were first to assess in vivo and longitudinally the effect of the combination of probiotics and rifaximin on a rat model of chronic HE; and second to compare the results obtained to groups of non-treated/rifaximin-only treated rats. 1H-MRS at high field combined with biochemical and behavioral tests were used.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords